Clinical Data on the Impact of Sotagliflozin on Stroke and Heart Attack Risk Among Four Lexicon-Sponsored Presentations at the American College of Cardiology 73rd Annual Scientific Session & Expo - Lexicon Pharmaceuticals (NASDAQ:LXRX)
THE WOODLANDS, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) today announced that four data presentations related to sotagliflozin, an inhibitor of two sodium glucose transport
Source: benzinga.com